Investment Opportunities.

U.S. Precision Medicine is currently seeking accredited investors to complete the pathway that will put a breakthrough patented cancer drug in the hands of the medical community via acquisition to a major pharma company.

  • TO DATE.

    To date, independent research through invitro & invivo studies verifies that DH20931:

    -- Provides n 80% reduction in cancer tumor volume

    -- 85% reduction in growth

    -- No toxicity

  • IN 12 MONTHS.

    Funding will complete IND research in 12 months:

    -- Additional research on dosage, combo studies with doxo and other cancer drugs for metastatic cancers

    -- Manufacturing, quality management and safety plans, etc. for final FDA application

  • NEXT 8 to 12 MONTHS.

    In the following 8 to 12 months, U.S. Precision Medicine will execute FDA Phase 1 before concluding a M&A via a major pharma partner or IPO.

Funding Details.

Contact for details: 

Chris Fey

469-400-6522 Chris.Fey@uspm.global

 

Fred Fey

386-438-4979 Fred.Fey@uspm.global